PE20151653A1 - Compuesto - Google Patents

Compuesto

Info

Publication number
PE20151653A1
PE20151653A1 PE2015001926A PE2015001926A PE20151653A1 PE 20151653 A1 PE20151653 A1 PE 20151653A1 PE 2015001926 A PE2015001926 A PE 2015001926A PE 2015001926 A PE2015001926 A PE 2015001926A PE 20151653 A1 PE20151653 A1 PE 20151653A1
Authority
PE
Peru
Prior art keywords
inflammatory diseases
compound
phosphoinositide
pi3k
kinases
Prior art date
Application number
PE2015001926A
Other languages
English (en)
Inventor
Stuart Thomas Onions
Alex Herman Copmans
Rudy Laurent Maria Broeckx
Alun John Smith
David Michel Adrien Taddei
Original Assignee
Respivert Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Respivert Ltd filed Critical Respivert Ltd
Publication of PE20151653A1 publication Critical patent/PE20151653A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La presente invencion se refiere al desarrollo de derivados de quinazolinona de formula (I), que son inhibidores de fosfoinositida 3-quinasas (PI3K), por lo que son utiles en el tratamiento de enfermedades inflamatorias, en particular, enfermedades inflamatorias respiratorias. La invencion ademas se extiende a composiciones y metodos de elaboracion de dichos compuestos
PE2015001926A 2013-03-15 2014-03-14 Compuesto PE20151653A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13275070 2013-03-15
EP13193372 2013-11-18

Publications (1)

Publication Number Publication Date
PE20151653A1 true PE20151653A1 (es) 2015-11-12

Family

ID=50349644

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015001926A PE20151653A1 (es) 2013-03-15 2014-03-14 Compuesto

Country Status (24)

Country Link
US (2) US9745306B2 (es)
EP (1) EP2970293B1 (es)
JP (1) JP6353856B2 (es)
KR (1) KR20150127607A (es)
CN (1) CN105229007B (es)
AU (1) AU2014229768B2 (es)
BR (1) BR112015019754A8 (es)
CA (1) CA2899812A1 (es)
CL (1) CL2015002606A1 (es)
EA (1) EA029218B1 (es)
ES (1) ES2640624T3 (es)
GT (1) GT201500218A (es)
HK (1) HK1214591A1 (es)
IL (1) IL240061A0 (es)
JO (1) JO3279B1 (es)
MX (1) MX2015012091A (es)
NI (1) NI201500134A (es)
PE (1) PE20151653A1 (es)
PH (1) PH12015501836A1 (es)
SG (1) SG11201505928YA (es)
TW (1) TW201522341A (es)
UA (1) UA116002C2 (es)
UY (1) UY35446A (es)
WO (1) WO2014140597A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ586418A (en) 2007-12-19 2012-09-28 Cancer Rec Tech Ltd Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
BR112012018415A2 (pt) 2010-02-01 2020-08-04 Cancer Research Technology Limited composto, composição, métodos de preparar uma composição e de tratamento, e, uso de um composto.
US9278950B2 (en) 2013-01-14 2016-03-08 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
PE20191245A1 (es) 2013-01-15 2019-09-18 Incyte Holdings Corp Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
SG11201601259YA (en) 2013-08-23 2016-03-30 Incyte Corp Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
EA201692557A1 (ru) 2014-07-04 2017-05-31 Люпин Лимитед Хинолизиноновые производные в качестве ингибиторов pi3k
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
AR105967A1 (es) 2015-09-09 2017-11-29 Incyte Corp Sales de un inhibidor de pim quinasa
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1140938T3 (da) 1999-01-11 2003-12-22 Univ Princeton Højaffinitetsinhibitorer for målvalidering og anvendelser heraf
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
PT1278748E (pt) 2000-04-25 2011-03-31 Icos Corp Inibidores de delta 3-cinase humana de fosfatidilinositol
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
JP3649395B2 (ja) 2000-04-27 2005-05-18 山之内製薬株式会社 縮合ヘテロアリール誘導体
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
JP2005509594A (ja) 2001-07-13 2005-04-14 バーチャル ドラッグ ディヴェロップメント、インコーポレイティッド Ｎａｄシンテターゼ阻害剤およびその使用
AU2002317377A1 (en) 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
US20040132732A1 (en) 2002-10-21 2004-07-08 Wei Han Quinazolinones and derivatives thereof as factor Xa inhibitors
WO2004080966A1 (ja) 2003-03-14 2004-09-23 Ono Pharmaceutical Co., Ltd. 含窒素複素環誘導体およびそれらを有効成分とする薬剤
US7122557B2 (en) 2003-03-18 2006-10-17 Bristol-Myers Squibb Company Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
US7429596B2 (en) 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
WO2005012221A1 (ja) 2003-08-04 2005-02-10 Ono Pharmaceutical Co., Ltd. ジフェニルエーテル化合物、その製造方法および用途
WO2005016348A1 (en) 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
WO2005016349A1 (en) 2003-08-14 2005-02-24 Icos Corporation Methods of inhibiting leukocyte accumulation
CA2552664A1 (en) 2004-01-08 2005-07-28 Michigan State University Methods for treating and preventing hypertension and hypertension-related disorders
CN101031569B (zh) 2004-05-13 2011-06-22 艾科斯有限公司 作为人磷脂酰肌醇3-激酶δ抑制剂的喹唑啉酮
EP1750714A1 (en) 2004-05-13 2007-02-14 Vanderbilt University Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
JP2008500338A (ja) 2004-05-25 2008-01-10 イコス・コーポレイション 造血細胞の異常増殖を治療及び／又は予防する方法
CA2569406A1 (en) 2004-06-04 2005-12-22 Icos Corporation Methods for treating mast cell disorders
CN101775013A (zh) 2004-09-13 2010-07-14 小野药品工业株式会社 含氮杂环衍生物及含有其作为活性成分的药物
AU2006214190A1 (en) 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
US20070063319A1 (en) 2005-09-19 2007-03-22 Bohumil Lojek Film stack and method for fabricating the same
CN101506211B (zh) * 2006-04-04 2013-05-22 加利福尼亚大学董事会 激酶拮抗剂
KR20150038395A (ko) 2006-04-04 2015-04-08 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 키나제 길항물질
AU2007269830A1 (en) 2006-06-29 2008-01-10 Schering Corporation Substituted bicyclic and tricyclic thrombin receptor antagonists
WO2008058402A1 (en) 2006-11-17 2008-05-22 Queen's University At Kingston Compounds and methods for treating protein folding disorders
WO2008067219A2 (en) 2006-11-29 2008-06-05 Kalypsys, Inc. Quinazolinone modulators of tgr5
WO2008104077A1 (en) 2007-02-28 2008-09-04 Methylgene Inc. Small molecule inhibitors of protein arginine methyltransferases (prmts)
WO2008140750A1 (en) 2007-05-10 2008-11-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
AU2009204483B2 (en) 2008-01-04 2014-03-13 Intellikine, Llc Certain chemical entities, compositions and methods
JP5731978B2 (ja) 2008-09-26 2015-06-10 インテリカイン， エルエルシー 複素環キナーゼ阻害剤
US20110269779A1 (en) 2008-11-18 2011-11-03 Intellikine, Inc. Methods and compositions for treatment of ophthalmic conditions
CA2745280A1 (en) 2008-12-04 2010-06-10 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders
WO2010065932A1 (en) 2008-12-05 2010-06-10 Designmedix, Inc. Modified chloroquines with single ring moiety or fused ring moiety
EP2411391A1 (en) 2009-03-24 2012-02-01 Gilead Calistoga LLC Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
RU2012104214A (ru) 2009-08-05 2013-09-10 Верситек Лимитед Противовирусные соединения и способы их получения и применения
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
HUE029420T2 (en) 2012-03-13 2017-02-28 Respivert Ltd Crystalline PI3 kinase inhibitors
US9227977B2 (en) * 2013-03-15 2016-01-05 Respivert Ltd. Phosphoinositide 3-kinase inhibitors

Also Published As

Publication number Publication date
US9745306B2 (en) 2017-08-29
CL2015002606A1 (es) 2016-03-04
EP2970293B1 (en) 2017-06-14
BR112015019754A2 (pt) 2017-07-18
HK1214591A1 (zh) 2016-07-29
NI201500134A (es) 2016-01-06
KR20150127607A (ko) 2015-11-17
AU2014229768B2 (en) 2018-01-04
UY35446A (es) 2014-09-30
CN105229007B (zh) 2017-08-25
AU2014229768A1 (en) 2015-08-06
JP6353856B2 (ja) 2018-07-04
CN105229007A (zh) 2016-01-06
EA029218B1 (ru) 2018-02-28
MX2015012091A (es) 2016-04-15
US20170334919A1 (en) 2017-11-23
WO2014140597A1 (en) 2014-09-18
CA2899812A1 (en) 2014-09-18
BR112015019754A8 (pt) 2019-11-12
IL240061A0 (en) 2015-09-24
UA116002C2 (uk) 2018-01-25
ES2640624T3 (es) 2017-11-03
JO3279B1 (ar) 2018-09-16
EP2970293A1 (en) 2016-01-20
TW201522341A (zh) 2015-06-16
PH12015501836A1 (en) 2015-11-09
JP2016510802A (ja) 2016-04-11
EA201591804A1 (ru) 2016-01-29
SG11201505928YA (en) 2015-09-29
US20160039826A1 (en) 2016-02-11
GT201500218A (es) 2017-09-21

Similar Documents

Publication Publication Date Title
PE20151653A1 (es) Compuesto
ECSP17073191A (es) Compuestos heterocíclicos como inhibidores de lsd1
GT201400178A (es) Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks
EA201890239A3 (ru) Фумараты как пролекарства и их применение при лечении различных заболеваний
CR20140111A (es) Heterociclilaminas como inhibidores de pi3k
CR20140132A (es) Derivados de pirrolopirimidina y purina
ECSP13012612A (es) Derivados de quinazolin-4-(3h)-ona utilizados como inhibidores de p13 cinasa
ECSP15045801A (es) Inhibidores de la phd de 6–(5–hidroxi–1h–pirazol–1–il)nicotinamida
CR20200276A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamientos de la hepatitis b (divisional exp. 2015-0059)
DOP2011000070A (es) Compuestos organicos
UY35395A (es) Inhibidores de bromodominios tetracíclicos
UY33430A (es) Derivados de piperidinona como inhibidores mdm2 para el tratamiento de cáncer
CR20150447A (es) Nuevos derivados de pirazol
BR112015029462A8 (pt) Inibidores de quinase
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
GEP201706623B (en) Pyrrolotriazinone derivatives as pi3k inhibitors
DOP2015000059A (es) Amino-quinolinas como inhibidores de cinasa
CR20150440A (es) Nuevos derivados de piridina
CR20150511A (es) Nuevos derivados de purina
BR112015029504A2 (pt) inibidores quinase
PE20151669A1 (es) Compuestos de azetidiniloxifenilpirrolidina
CY1121116T1 (el) Νεα μεθοδος για την συνθεση αγομελατινης
NI201500176A (es) Derivados de prodroga de triazolpiridinas sustituidas
UY37444A (es) Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y su uso
CR20150028A (es) Derivados de ariletinilo

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed